The biggest private biotech funding round of November 2024 went to Metsera, which raised $215 million in series B funding. The company is focused on advancing the next generation of therapies for ...
Progressing a drug through clinical trials relies on a robust evidence generation plan that includes a strong trial design, accurate patient recruitment and treatment effect assumptions, and ...
Bugworks, which is headquartered in the U.S. with subsidiaries in India and Australia, specializes in the development of antibiotics that could address the growing crisis of antimicrobial resistance.
Asking whether China is the future of the biotech industry might seem counterintuitive, considering the current biotech geopolitical context. If you haven’t followed this series of events, a ...